Loading...

ELTX ELICIO THERAPEUTICS INC Operational Disruptions 8-K Filing

LC T

LTX

ELICIO THERAPEUTICS INC

(ELTX)

2024 8-K

Financial Results

Positive Trial Results

Financial Statements

Product Expansion

Debt-Equity Swaps

Financial Statements

Financial Results

Management Change

Stock Conversion

Corporate Presentation

Corporate Update

Study Enrollment Complete

Annual Meeting Results

Financial Results

Data Presentation

Annual Meeting Update

Management Change

Financial Results

Convertible Note Issuance

Underwriting Agreement for ...

Preliminary Disease-Free Su...

Other Special Situation

Financial Results Announcement

Financial Results Announcement

Subscription Agreement

Compensation Adjustments an...

Poster Presentation Announc...

Subscription Agreement with...

Financial Results Announcement

Departure of Directors or C...

Departure of Directors

Financial Results Announcement

Interim Data Announcement

Merger and Name Change

Merger Agreement

Merger Agreement

Merger Agreement

Merger Agreement

Termination of Lease Agreement

Merger Agreement

External Links:

Elicio Therapeutics announced preliminary disease-free survival analysis from its ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P, a therapeutic cancer vaccine candidate.

AI Assistant

ELICIO THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.